ImClone initiate Phase II study of IGF-1R MAb for Advanced Soft Tissue Sarcoma « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

ImClone initiate Phase II study of IGF-1R MAb for Advanced Soft Tissue Sarcoma

Posted on July 7, 2008 by crimsoncanary

ImClone Systems have announced the start of a Phase II clinical trial of IMC-A12, its IGF-1R monoclonal antibody in adolescents and adult patients with several types of soft tissue sarcoma.

Filed under: Kinase receptor | Tagged: IGF-1R, IMC-A12, IMCA12, ImClone, MAb, Monoclonal, Phase II, Sarcoma

« mTor inhibitor Rapamycin rescues synaptic plasticity and behavioral deficits in a model of tuberous sclerosis Hana Biosciences Menadione found to restore kinase without inhibiting the Anti-Tumor Effect of Erlotinib »